San Diego-based biotechnology company Samumed has recently announced that it will be moving to phase 3 clinical trials of its drug lorecivivint (SM04690) for the treatment of knee osteoarthritis. What is osteoarthritis? Osteoarthritis is the most common form of arthritis in the knee and a leading cause of adult disability, particularly among older people. This…

Today, we were pleased to hear that Samumed, a San Diego-based biotech company working on regenerative medicine, has just raised $438 million towards developing anti-aging therapies. SAN DIEGO – August 6, 2018 – Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD